Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARTS-2: Long-Term Extension of Sildenafil in Pediatric PAH
NCT00159874Phase 3Completed
- Sponsor
- Viatris
- Start
- Jan 2004
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of ASP-001 in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Viatris. Primary endpoints: Number of Participants Reporting at Least One Adverse Event, Number of Participants Reporting at Least One Serious Adverse Event and 3 more. Started Jan 2004; status: completed.
02
Drugs
ASP-001
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00159874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00159874.